Bio-Techne Corporation (TECH)

NASDAQ

$58.70

+$0.19 (0.32%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$57.42$60.27

Open $58.59

52 Week Range

$46.01$79.28

Previous Close $58.51

Market Cap9.20B

Volume1.15M

Avg Volume2.20M

P/E (TTM)117.02

EPS (TTM)$0.50

Dividend / Yield$0.32 (0.55%)

Dividend StreakN/A

Latest Press Releases for Bio-Techne Corporation

DEC92025

Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Source: PRNewsWire•6 days ago

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports complex assay configurations Strengthens Bio-Techne's...

NOV262025

CMB.TECH announces Q3 2025 results

Source: GlobeNewsWire•19 days ago

CMB.TECH ANNOUNCES Q3 2025 RESULTS SOFT SUMMER, FOLLOWED BY ROARING TANKER AND DRY BULK MARKETS ANTWERP, Belgium, 26 November 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO)...

NOV252025

Bio-Techne to Present at Upcoming Investor Conferences

Source: PRNewsWire•20 days ago

MINNEAPOLIS , Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 8th Annual Evercore Healthcare Conference 2025 December 2, 2025 8:20 AM EST Citi's 2025 Glob...

NOV182025

Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio

Source: PRNewsWire•27 days ago

Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars a...

NOV142025

PRESS RELEASE: CMB.TECH announces Q3 2025 results on 26/11/2025

Source: GlobeNewsWire•31 days ago

Antwerp, Nov. 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its third quarter 2025 earnings prior to market opening on Wednesday 26 November 2025 and will host a conference c...

NOV62025

Bio-Techne to Present at Upcoming Investor Conferences

Source: PRNewsWire•39 days ago

MINNEAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Stifel 2025 Healthcare C...

NOV52025

Bio-Techne Releases First Quarter Fiscal 2026 Results

Source: PRNewsWire•40 days ago

MINNEAPOLIS , Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased...

NOV52025

BIO-TECHNE DECLARES DIVIDEND

Source: PRNewsWire•40 days ago

MINNEAPOLIS , Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable N...

NOV42025

AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

Source: PRNewsWire•41 days ago

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platfo...

NOV32025

ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics

Source: PRNewsWire•42 days ago

ST. PAUL, Minn. , Nov. 3, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant....